Analysts Set Expectations for SI-BONE FY2025 Earnings

SI-BONE, Inc. (NASDAQ:SIBN) – Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for SI-BONE in a research report issued on Tuesday, February 25th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($0.64) per share for the year, down from their previous forecast of ($0.19). Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $49.00 million during the quarter, compared to analyst estimates of $48.87 million.

A number of other analysts have also recently commented on SIBN. Needham & Company LLC lifted their target price on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday. Truist Financial reiterated a “buy” rating and issued a $22.00 target price (up from $18.00) on shares of SI-BONE in a research note on Tuesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $24.50.

SI-BONE Trading Down 1.6 %

Shares of NASDAQ SIBN opened at $18.15 on Thursday. The business has a fifty day moving average price of $15.91 and a 200 day moving average price of $14.74. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE has a 1-year low of $11.70 and a 1-year high of $19.19. The stock has a market capitalization of $761.17 million, a P/E ratio of -19.73 and a beta of 1.17.

Insider Activity

In related news, CFO Anshul Maheshwari sold 5,304 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the sale, the chief financial officer now owns 189,319 shares of the company’s stock, valued at $2,633,427.29. This trade represents a 2.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the transaction, the insider now owns 222,814 shares in the company, valued at approximately $3,097,114.60. The trade was a 1.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,311 shares of company stock worth $130,356. 3.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On SI-BONE

Large investors have recently modified their holdings of the stock. Jane Street Group LLC raised its stake in shares of SI-BONE by 29.0% in the 3rd quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock valued at $1,081,000 after purchasing an additional 17,410 shares in the last quarter. Millrace Asset Group Inc. acquired a new position in shares of SI-BONE during the third quarter valued at $1,056,000. Champlain Investment Partners LLC raised its position in shares of SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after buying an additional 358,821 shares in the last quarter. Impax Asset Management Group plc boosted its stake in SI-BONE by 41.3% during the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock valued at $10,604,000 after purchasing an additional 221,604 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of SI-BONE by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock worth $265,000 after purchasing an additional 1,745 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.